不同剂量雷珠单抗玻璃体腔注射治疗湿性年龄相关性黄斑变性的临床效果  

Clinical Effect of Vitreous Injection of Different Doses of Ramizumab in the Treatment of Wet Age-related Macular Degeneration

作　　者：毛蕾 MAO Lei(Xinyu People’s Hospital,Jiangxi Province,Xinyu 338000,China)

机构地区：[1]江西省新余市人民医院,江西新余338000

出　　处：《中国医学创新》2022年第26期39-43,共5页Medical Innovation of China

基　　金：新余市科学技术局项目(20203090857)。

摘　　要：目的:比较不同剂量雷珠单抗玻璃体腔注射治疗湿性年龄相关性黄斑变性的临床效果。方法:选取2019年1月-2020年8月新余市人民医院收治的88例(88眼)湿性年龄相关性黄斑变性患者,采用随机数字表法将其分为A组和B组,各44例(44眼)。两组患者均接受雷珠单抗玻璃体腔注射治疗,1~3次,在每次治疗剂量的选择上,A组予以0.5 mg,B组予以1.0 mg。比较两组各项疗效观察指标、视网膜中央动脉眼血流动力学指标、并发症及复发情况。结果:治疗后3个月,两组最佳矫正视力(BCVA)、a波振幅、b波振幅均高于治疗前,视网膜黄斑中心凹厚度(CMT)均低于治疗前,且B组BCVA、a波振幅、b波振幅均高于A组,CMT低于A组,差异均有统计学意义(P<0.05)。治疗后3个月,两组收缩期峰值流速(PSV)、舒张末期流速(EDV)均高于治疗前,阻力指数(RI)均低于治疗前,且B组PSV、EDV均高于A组,RI低于A组,差异均有统计学意义(P<0.05)。B组复发率低于A组,差异有统计学意义(P<0.05)。两组并发症发生率比较,差异无统计学意义(P>0.05)。结论:0.5 mg和1.0 mg两种剂量雷珠单抗玻璃体腔注射均可有效治疗湿性年龄相关性黄斑变性,后者在提高视力、减小CMT厚度上具有优势,可能与改善眼血流动力学有关,且安全性尚可,值得推广应用。Objective:To compare the efficacy of vitreous injection of different doses of Ramizumab in the treatment of wet age-related macular degeneration.Method:A total of 88 patients (88 eyes) with wet age-related macular degeneration admitted to Xinyu People’s Hospital from January 2019 to August 2020 were selected,they were divided into group A and group B according to random number table method,with 44 cases (44 eyes) in each group.Patients in both groups received vitreous injection of Ramizumab for 1 to 3 times,in the selection of each treatment doses,group A was given 0.5 mg and group B was given 1.0 mg.The efficacy indexes,ocular hemodynamic indexes of central retinal artery,complications and recurrence were compared between the two groups.Result:3 months after treatment,the best corrected visual acuity (BCVA),amplitude of a wave and amplitude of b wave in both groups were higher than those before treatment,and the central macular thickness (CMT) in both groups were lower than those before treatment,the BCVA,amplitude of a wave and amplitude of b wave in the group B were higher than those in the group A,and the CMT in the group B was lower than that in the group A,the differences were statistically significant (P<0.05).3 months after treatment,the peak systolic velocity (PSV) and end-diastolic velocity (EDV) in both groups were higher than those before treatment,and the resistance index (RI) in both groups were lower than that before treatment,the PSV and EDV in the group B were higher than those in the group A,and the RI in the group B was lower than that in the group A,the differences were statistically significant (P<0.05).The recurrence rate in the group B was lower than that in the group A,the difference was statistically significant (P<0.05).There was no significant difference in the incidence of complications between the two groups (P>0.05).Conclusion:Vitreous injection of 0.5 mg and 1.0 mg of Ramizumab is effective in the treatment of wet age-related macular degeneration,the latter has advantages in impro

关 键 词：湿性年龄相关性黄斑变性 雷珠单抗 玻璃体腔 眼血流动力学 

分 类 号：R774.5[医药卫生—眼科]